Nucleic acid-lipid nanoparticles for atomized inhalation and preparation method and application thereof

By using specific formulas of lipid nanoparticles and water-soluble excipients in atomization inhalation technology, the problem of lipid nanoparticles being damaged by shear force during atomization process is solved, and antisense oligonucleotide drugs are realized Effective delivery in the lungs and significant inhibition of lung cancer cells ensures the biocompatibility and safety of the drug.

CN118634207BActive Publication Date: 2024-11-26HANGZHOU TIANLONG PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411125688.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-15
Publication Date
2024-11-26
Estimated Expiration
2044-08-15

AI Technical Summary

Technical Problem

The prior art is difficult to effectively deliver antisense oligonucleotide drugs to lung target cells through atomization inhalation, and during the atomization process, the lipid nanoparticles are damaged by shear force, resulting in increased particle size and drug leakage, affecting the therapeutic effect. .

Method used

Lipid nanoparticles containing 40-60 mole % non-ionizable cationic lipids, 10-20 mole % neutral lipids, 1-5 mole % long circulating lipids and 30-50 mole % cholesterol combined with water-soluble The chemical agent, forming a stable pharmaceutical composition, can maintain consistency of particle size and encapsulation rate during the atomization process, ensuring effective delivery of the drug in the lungs.

Benefits of technology

The significant inhibition of lung cancer cells after atomization and inhalation has been achieved, and the biocompatibility is good, it is not easy to produce inflammation and irritation, and it has good safety and stability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118634207B_ABST
    Figure CN118634207B_ABST
Patent Text Reader

Abstract

The present disclosure provides a nucleic acid-lipid nanoparticle for atomized inhalation and a preparation method and application thereof, wherein the nucleic acid-lipid nanoparticle comprises a lipid, a nucleic acid encapsulated in the lipid, and a dispersion system solution to which a water-soluble excipient is added. The nucleic acid-lipid nanoparticle can deliver a target gene in an aerosol manner through a vibrating mesh nebulizer or a soft mist inhaler, and the atomization process can ensure the stability of the particle size, PDI and encapsulation rate, and can achieve efficient lung delivery, and the particle size and encapsulation rate do not change significantly when stored at 2-8°C for 6 months, and the stability is good.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure relates to the field of biomedicine, and in particular, to a nucleic acid-lipid nanoparticle pharmaceutical composition for aerosol inhalation, and a preparation method and application thereof. Background Art

[0002] Antisense oligodeoxynucleotides (ASO) are a class of artificially synthesized oligonucleotide fragments with a length of 15 to 30 nucleotides. They mainly interfere with the transcription and translation of target genes through the principle of base complementary pairing, thereby achieving targeted gene therapy. ASO has the advantages of abundant candidate targets, rational directional design, high efficiency in vitro and in vivo, and large-scale artificial synthesis, and is considered to be a highly promising gene therapy drug.

[0003] Antisense oligonucleotides alone have poor stability and no specific tissue targeting, which makes them easily degraded by nucleases in the body and cannot play a good therapeutic role. In recent years, with the development of new delivery technologies, the research and development of antisense oligonucleotide drugs has made breakthrough progress. There are many types of nucleic acid delivery vectors, including viral vectors, lipid nanoparticles, lipid-polymer hybrid nanoparticles, nanostructured lipid carriers, cationic polymers, exosome nanovesicles, and protein carriers. At present, lipid nanoparticles (LNP, lipid nanoparticle) are one of the most widely used delivery systems for nucleic acid drug research. LNP can safely and effectively deliver nucleic acids and is usually composed of four lipids with similar molar ratios: including cationic lipids, phospholipids, cholesterol and PEG-lipids.

[0004] Compared with other delivery methods, inhaled LNP can maximize the concentration of nucleic acid drugs in the lungs and can be used to treat a variety of diseases, such as cystic fibrosis (CF), tuberculosis, chronic obstructive pulmonary disease and lung cancer. However, the successful development of inhaled LNP faces many difficulties and challenges. This is because no matter what form of atomization, such as ultrasonic atomization, compressed air atomization, vibrating mesh atomization, soft mist inhaler atomization, etc., LNP will be damaged by shear force during the atomization process. This shear damage may cause the LNP particle size and PDI to increase, nucleic acid drug leakage, and ultimately affect its transfection effect. Whether LNP can maintain its function after atomization, whether antisense oligonucleotides can be delivered to target cells, and whether proteins can be expressed in cells, etc., are technical problems that need to be solved urgently. Summary of the invention

[0005] The purpose of the present disclosure is to provide an LNP pharmaceutical composition containing nucleic acid, which is suitable for delivering DNA or therapeutic genes for targeted gene therapy to the lungs in a nebulized inhalation manner, and can remain intact during nebulization, so that the nucleic acid drug can effectively exert its function after inhalation.

[0006] In one aspect, the present disclosure provides a pharmaceutical composition comprising a lipid, a nucleic acid encapsulated in the lipid, and a dispersion solution to which a water-soluble excipient is added;

[0007] The lipids include 40-60 mol % of non-ionizable cationic lipids, 10-20 mol % of neutral lipids, 1-5 mol % of long-circulating lipids and 30-50 mol % of cholesterol;

[0008] The non-ionizable cationic lipid is (2,3-dioleoyl-propyl)-trimethylammonium-chloride (DOTAP), the neutral lipid is distearoyl phosphatidylcholine (DSPC), and the long-circulating lipid is dimyristoylglycerol-3-methoxypolyethylene glycol 2000 (DMG-PEG2k).

[0009] The pharmaceutical composition provided by the present disclosure has high versatility. When using different lipid dosages and formulations, it can be ensured that it can withstand the shear force during the nebulization process and achieve consistency in particle size, dispersion (PDI) and encapsulation efficiency (EE) before and after nebulization.

[0010] Optionally, the dosage ratio of the non-ionizable cationic lipid to the nucleic acid is expressed as an N / P ratio, and the N / P ratio is (1:1)-(30:1), preferably (3:1)-(10:1).

[0011] Optionally, the non-ionizable cationic lipid refers to a lipid molecule that can be permanently positively charged, and can also be any one selected from dioleoylpropyltrimethylammonium chloride (DOTMA) and 1,2-dioleyl-3-dimethylamino-propane (DODAP);

[0012] Optionally, the neutral lipid may also be at least one selected from dipalmitoylphosphatidylcholine (DPPC) and dioleoylphosphatidylethanolamine (DOPE);

[0013] Optionally, the nucleic acid is any one selected from the group consisting of mRNA, siRNA, DNA, miRNA, antisense oligonucleotide and non-coding RNA, preferably any one selected from the group consisting of siRNA and antisense oligonucleotide, more preferably antisense oligonucleotide.

[0014] Preferably, the nucleic acid is CT102, and the nucleotide sequence of CT102 is 5'-TCCTCCGGAGCCAGACTTCA-3'.

[0015] Optionally, the particle size of the pharmaceutical composition is 50-300 nm, preferably 50-200 nm, and the polydispersity index of the pharmaceutical composition is not greater than 0.3.

[0016] Optionally, the dispersion system solution is at least one selected from Tris buffer, DPBS buffer, HEPES buffer, PBS buffer, citrate buffer, phosphate buffer, carbonate buffer and acetate buffer.

[0017] Optionally, the water-soluble excipient includes at least one of sucrose, trehalose, polyvinyl alcohol, Tween 80, Tween 20, poloxamer 188, Triton, sodium dodecyl sulfate, sodium chloride, potassium chloride and glycine; preferably at least one of Tween 80, poloxamer 188 and Triton;

[0018] If the excipient is Tween 80, the excipient is used at a concentration of 0.01-0.5% (w / v), preferably 0.05-0.15% (w / v);

[0019] If the excipient is poloxamer 188, the excipient is used at a concentration of 0.05-1% (w / v), preferably 0.3-0.7% (w / v);

[0020] If the excipient is Triton, the excipient is used at a concentration of 0.01-0.5% (w / v), preferably 0.05-0.15% (w / v).

[0021] The pharmaceutical composition containing non-ionizable cations prepared by the present invention has good aerosol stability, and further, by adding excipients to the dispersion system, the lipids in the prepared pharmaceutical composition can withstand the shear force during the aerosolization process, and the particle size, PDI and EE remain unchanged before and after aerosolization; the above-mentioned pharmaceutical composition is refrigerated at 2-8°C for 6 months, the particle size increases within 3 nm, the PDI has no obvious change, the encapsulation rate decreases within 3%, the change is not significant, and the stability is good, which effectively solves the technical problem that the aerosol inhalation LNP in the market cannot withstand the aerosol shear force and has poor stability.

[0022] In another aspect, the present disclosure provides a method for preparing the above-mentioned pharmaceutical composition, the method comprising the following steps:

[0023] S1, dissolving the lipid in an organic solvent to obtain a first dispersion;

[0024] S2, dissolving the nucleic acid in the first dispersion system solution to obtain a second dispersion solution;

[0025] S3, mixing the first dispersion liquid and the second dispersion liquid using a microfluidic method to obtain a lipid nanoparticle intermediate solution;

[0026] S4. Use the second dispersed system solution to ultrafilter the lipid nanoparticle intermediate solution to remove the organic solvent, add the water-soluble excipient, and mix until uniform.

[0027] Optionally, the organic solvent is any one selected from ethanol, acetone and N, N-dimethylformamide.

[0028] Optionally, the first dispersed system solution is at least one selected from a citrate buffer and an acetate buffer;

[0029] The second dispersed system solution is at least one selected from Tris buffer, DPBS buffer and HEPES buffer.

[0030] On the other hand, the present disclosure provides the use of the above-mentioned pharmaceutical composition and / or the pharmaceutical composition prepared by the above-mentioned method in the preparation of an anti-tumor drug, wherein the administration method of the anti-tumor drug is atomization inhalation;

[0031] The atomizing inhalation device used in the present disclosure is commercially available, and the atomizing inhalation device is any one selected from a compression nebulizer, a vibrating mesh nebulizer, and a soft mist inhaler; preferably a vibrating mesh nebulizer or a soft mist inhaler.

[0032] The term "RNA therapy" disclosed in this disclosure refers to the use of RNA-based molecules to treat or prevent diseases. Its targeted drugs mainly include small molecule drugs targeting RNA, antisense oligonucleotides (ASO), small interfering RNA (siRNA), microRNA (miRNA), RNA aptamers (Aptamer), short activating RNA (saRNA), genome editing, exogenously expressed and delivered mRNA, etc.

[0033] The term "delivery system" in the present disclosure refers to a preparation or composition that regulates the distribution of biologically active ingredients in space, time and dosage in an organism.

[0034] Through the above technical scheme, the pharmaceutical composition containing non-ionizable cations provided by the present disclosure has good atomization stability, can achieve effective deposition in the lungs after atomization inhalation, has a significant proliferation inhibitory effect on lung cancer cells, has good biocompatibility, is not prone to inflammation and irritation, and has good safety.

[0035] Other features and advantages of the present disclosure will be described in detail in the following detailed description. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] The accompanying drawings are used to provide a further understanding of the present disclosure and constitute a part of the specification. Together with the following specific embodiments, they are used to explain the present disclosure but do not constitute a limitation of the present disclosure. In the accompanying drawings:

[0037] Figure 1 1 is a graph showing the particle size results of the model sample before and after atomization in Example 1 of the present invention;

[0038] Figure 2 It is the particle size result diagram of different DOTAP prescription dosages before and after atomization in Example 2-3 of the present invention;

[0039] Figure 3 This is a graph showing the particle size results of the stability of the formulation of Example 1 of the present invention at 2-8°C;

[0040] Figure 4 This is a graph showing the weight change of mice after aerosol inhalation administration of the model sample of Example 1 of the present invention;

[0041] Figure 5 This is a graph showing the tumor inhibition results after aerosol inhalation administration of the model sample of Example 1 of the present invention to mice. DETAILED DESCRIPTION

[0042] The specific embodiments of the present disclosure are described in detail below. It should be understood that the specific embodiments described herein are only used to illustrate and explain the present disclosure, and are not used to limit the present disclosure.

[0043] In one aspect, the present disclosure provides a pharmaceutical composition comprising a lipid, a nucleic acid encapsulated in the lipid, and a dispersion solution to which a water-soluble excipient is added;

[0044] The lipids include 40-60 mol % of non-ionizable cationic lipids, 10-20 mol % of neutral lipids, 1-5 mol % of long-circulating lipids and 30-50 mol % of cholesterol;

[0045] The non-ionizable cationic lipid is (2,3-dioleoyl-propyl)-trimethylammonium-chloride, the neutral lipid is distearoylphosphatidylcholine, and the long-circulating lipid is dimyristoylglycerol-3-methoxypolyethylene glycol 2000.

[0046] Optionally, the dosage ratio of the non-ionizable cationic lipid to the nucleic acid is expressed as an N / P ratio, and the N / P ratio is (1:1)-(30:1), preferably (3:1)-(10:1).

[0047] Optionally, the non-ionizable cationic lipid may also be any one selected from dioleylpropyl trimethylammonium chloride and 1,2-dioleyl alcohol-3-dimethylamino-propane;

[0048] The neutral lipid may also be at least one selected from dipalmitoylphosphatidylcholine and dioleoylphosphatidylethanolamine.

[0049] Optionally, the nucleic acid is any one selected from the group consisting of mRNA, siRNA, DNA, miRNA, antisense oligonucleotide and non-coding RNA, preferably any one selected from the group consisting of siRNA and antisense oligonucleotide, more preferably antisense oligonucleotide.

[0050] Preferably, the nucleic acid is CT102, and the nucleotide sequence of CT102 is 5'-TCCTCCGGAGCCAGACTTCA-3'.

[0051] Optionally, the particle size of the pharmaceutical composition is 50-300 nm, preferably 50-200 nm, and the polydispersity index of the pharmaceutical composition is not greater than 0.3.

[0052] Optionally, the dispersion system solution is at least one selected from Tris buffer, DPBS buffer, HEPES buffer, PBS buffer, citrate buffer, phosphate buffer, carbonate buffer and acetate buffer.

[0053] Optionally, the water-soluble excipient includes at least one of sucrose, trehalose, polyvinyl alcohol, Tween 80, Tween 20, poloxamer 188, Triton, sodium dodecyl sulfate, sodium chloride, potassium chloride and glycine; preferably at least one of Tween 80, poloxamer 188 and Triton;

[0054] If the excipient is Tween 80, the excipient is used at a concentration of 0.01-0.5% (w / v), preferably 0.05-0.15% (w / v);

[0055] If the excipient is poloxamer 188, the excipient is used at a concentration of 0.05-1% (w / v), preferably 0.3-0.7% (w / v);

[0056] If the excipient is Triton, the excipient is used at a concentration of 0.01-0.5% (w / v), preferably 0.05-0.15% (w / v).

[0057] In another aspect, the present disclosure provides a method for preparing the above-mentioned pharmaceutical composition, the method comprising the following steps:

[0058] S1, dissolving the lipid in an organic solvent to obtain a first dispersion;

[0059] S2, dissolving the nucleic acid in the first dispersion system solution to obtain a second dispersion solution;

[0060] S3, mixing the first dispersion liquid and the second dispersion liquid using a microfluidic method to obtain a lipid nanoparticle intermediate solution;

[0061] S4. Use the second dispersed system solution to ultrafilter the lipid nanoparticle intermediate solution to remove the organic solvent, add the water-soluble excipient, and mix until uniform.

[0062] Optionally, the organic solvent is any one selected from ethanol, acetone and N, N-dimethylformamide.

[0063] Optionally, the first dispersed system solution is at least one selected from a citrate buffer and an acetate buffer;

[0064] The second dispersed system solution is at least one selected from Tris buffer, DPBS buffer and HEPES buffer.

[0065] On the other hand, the present disclosure provides the use of the above-mentioned pharmaceutical composition and / or the pharmaceutical composition prepared by the above-mentioned method in the preparation of an anti-tumor drug, wherein the anti-tumor drug is administered by atomization inhalation;

[0066] The device for atomization inhalation is any one selected from a compression nebulizer, a vibrating mesh nebulizer and a soft mist inhaler.

[0067] Definitions of professional terms for reagents used in this disclosure:

[0068] DOTAP: Chinese name: (2,3-Dioleoyloxy-propyl)-trimethylammonium-chloride; English name: (2,3-Dioleoyloxy-propyl)-trimethylammonium-chloride, CAS: 132172-61-3, chemical structure is as follows:

[0069]

[0070] DOTMA: Chinese name: dioleoylpropyl trimethylammonium chloride, English name: N,N,N-trimethyl-2,3-bis(octadec-9-en-1-yloxy)propan-1-aminium chloride, CAS: 104872-42-6;

[0071] DODMA: Chinese name: 1,2-dioleyloxy-3-dimethylamino-propane, English name: 1,2-dioleyloxy-3-dimethylaminopropane, CAS: 104162-47-2;

[0072] DSPC: Chinese name: Distearoylphosphatidylcholine, English name: distearoylphosphatidylcholine, 1,2-distearoyl-sn-glycero-3-phosphocholine, CAS: 816-94-4;

[0073] DOPE: Chinese name: 1,2-dioleoyl-SN-glycero-3-phosphoethanolamine; English name: 1,2-dioleoylsn-glycero-3-phosphoethanolamine, CAS: 4004-05-1;

[0074] DPPC: Chinese name: Dipalmitoylphosphatidylcholine; English name: 1,2-dipalmitoy1-sn-glycero3-phosphocholine, CAS: 63-89-8;

[0075] DMG-PEG2k: Chinese name: dimyristoylglycerol-3-methoxypolyethylene glycol 2000; English name: 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000, CAS: 160743-62-4;

[0076] PEG: Chinese name: polyethylene glycol; English name: Polyethylene glycol;

[0077] Tris buffer: Chinese name: tris(hydroxymethyl)aminomethane; English name: 2-Amino-2-(hydroxymethyl)-1,3-propanediol, CAS number: 77-86-1;

[0078] DPBS: Dulbecco's phosphate buffered saline;

[0079] PBS buffer: main components are Na2HPO4, KH2PO4, NaCl and KCl;

[0080] HEPEs buffer: Chinese name: 4-hydroxyethylpiperazineethanesulfonic acid; English name: 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid, CAS number: 7365-45-9;

[0081] Citrate Buffer: The main components of citrate buffer are citric acid and sodium citrate;

[0082] LNP is lipid nanoparticle; N / P ratio is the ratio of carrier amine nitrogen to antisense oligonucleotide phosphate; T80 is Tween 80; P188 is poloxamer 188; PDI is polydispersity index; EE% is encapsulation efficiency; RT is room temperature.

[0083] The present disclosure is further described in detail by the following examples. The raw materials used in the examples can be obtained through commercial channels. The experimental data of the inter-group comparison in the following examples have a P value < 0.05, and the difference is statistically significant.

[0084] Example 1

[0085] This example is used to prepare the pharmaceutical composition CT102-LNP.

[0086] (1) The encapsulated antisense oligonucleotide drug is CT102, and its nucleotide sequence is: 5'-TCCTCCGGAGCCAGACTTCA-3' SEQ ID NO.1; CT102 is a sodium salt of thiodeoxy oligonucleotide with a length of 20 nucleotides, which targets the messenger RNA (mRNA) of human insulin-like growth factor type 1 receptor (IGF1R) and inhibits the activity of IGF1R through antisense action, thereby causing tumor cell apoptosis or inducing its differentiation, thereby achieving the purpose of treating the disease.

[0087] (2) Preparation method:

[0088] Cationic lipid DOTAP (Aiweituo (Shanghai) Pharmaceutical Technology Co., Ltd.), neutral lipid DSPC (NipponFine Chemical, CO., LTD.) and cholesterol (Aiweituo (Shanghai) Pharmaceutical Technology Co., Ltd.) and PEG lipid DMG-PEG2k (SINOPEG) were prepared into lipid ethanol solution at a molar ratio of 50 / 10 / 38.5 / 1.5, the antisense oligonucleotide drug was diluted with 100mM acetate buffer (pH4.0), and the alcohol-water phase was mixed with a microfluidic device at a volume ratio of 1:3. The antisense oligonucleotide drug concentration of the obtained LNP solution was 0.2mg / mL and the N / P ratio was 6:1. After encapsulation on the microfluidic device, Tris buffer was used to ultrafilter to remove ethanol, and Tween 80 was added to make the excipient concentration in the dispersed solution 0.1% (w / v) to prepare the LNP solution.

[0089] This example further measured the mass of the atomized pharmaceutical composition CT102-LNP.

[0090] (3) Nebulization process: The CT102-LNP prepared in Example 1 containing 0.1% T80 (w / v) as an excipient was used as a model sample. The sample was atomized using a vibrating mesh nebulizer (VAPO) at RT, and the aerosol droplets were collected by condensation in a sample tube.

[0091] (4) Determination of physical and chemical properties:

[0092] Determination of particle size and PDI:

[0093] The particle size and PDI of the CT102-LNP sample before and after atomization were detected using dynamic light scattering (DLS) in a nano-laser particle size analyzer (manufacturer: MALVERN; model: ZSU3305). The detection parameters are set as shown in Table 1:

[0094] Table 1 Detection parameters

[0095]

[0096] (5) Encapsulation efficiency determination:

[0097] The sample was diluted to 2.8 μg / mL, and one part was mixed with an equal volume (50 μL) of Triton X-100 to fully break the emulsion for the determination of the total antisense nucleic acid concentration, and the other part was mixed with an equal volume (50 μL) of TE (Tris-EDTA) for the determination of the free unencapsulated antisense nucleic acid concentration. After the samples with TE (Tris-EDTA) and Triton X-100 were incubated at 37°C for a certain period of time, 100 μL of Ribogreen reagent diluted 200 times was added, and after centrifugation to remove bubbles, the fluorescence value was measured using a multifunctional microplate reader at an excitation wavelength of 485 nm and an emission wavelength of 528 nm, and the plate was read. The experimental results are shown in Tables 2 and Figure 1 shown.

[0098] Table 2 Particle size, PDI and encapsulation efficiency results of CT102-LNP before and after atomization.

[0099]

[0100] It can be seen from the above table that in the presence of 0.1% (w / v) Tween 80, the particle size of DOTAP cationic lipid LNP after atomization is less than 200 nm, and the encapsulation efficiency remains basically unchanged, with good stability.

[0101] Example 2-3

[0102] In Examples 2 and 3, the dosage of each lipid in the pharmaceutical composition was changed to verify that the pharmaceutical composition has universal applicability.

[0103] According to the method of Example 1, LNPs with different lipid contents were prepared and the LNP samples were atomized. The experimental results are shown in Tables 3 and Figure 2 (The left picture is Example 2, and the right picture is Example 3) as shown:

[0104] Table 3 LNP component ratio, particle size before and after atomization, PDI and encapsulation efficiency results

[0105]

[0106] It can be seen from Table 3 that the dosage of DOTAP in the prescription is in the range of 40-60 mol%, the particle size of LNP after atomization is less than 200 nm, and the encapsulation efficiency remains unchanged, and the cationic lipid has a high applicability.

[0107] Embodiment 4-5

[0108] The preparation methods of Examples 4 and 5 are the same as those of Example 1, with the only difference being that the N / P ratio of the pharmaceutical composition prepared in Example 1 is different.

[0109] The LNP solution was prepared according to the same formula ratio and method as in Example 1, and the LNP sample was atomized. The experimental results are shown in Table 4.

[0110] Table 4 LNP component ratio, particle size before and after atomization, PDI and encapsulation efficiency results

[0111]

[0112] It can be seen from the above table that when the N / P ratio of the DOTAP prescription is 3:1 and 15:1, the particle size of the LNP after atomization is less than 200 nm, and the encapsulation efficiency remains unchanged. Combined with the results of Example 1 and Example 4-5, the cationic lipid in the pharmaceutical composition has a stable atomization effect in the dosage range of 40%-60% and the N / P ratio in the range of 3:1-15:1.

[0113] Embodiment 6-7

[0114] The preparation methods of Examples 6 and 7 are the same as those of Example 1, with the only difference being that the pharmaceutical compositions of the present examples contain different amounts of PEG lipid and cholesterol.

[0115] The LNP solution was prepared in the same manner as in Example 1, and the LNP sample was atomized. The experimental results are shown in Table 5.

[0116] Table 5 LNP components, particle size before and after atomization, PDI and encapsulation efficiency results

[0117]

[0118] As can be seen from the above table, combined with the results of Example 1, the PEG lipid content is in the range of 1.5-5 mol%, and the pharmaceutical composition has a stable atomization effect.

[0119] Examples 8-12

[0120] The preparation methods of the pharmaceutical compositions of Examples 8-12 are the same as those of Example 1, except that the excipient content in the dispersion system is different. The excipient content, particle size of the prepared pharmaceutical compositions, PDI and encapsulation efficiency are shown in Table 6.

[0121] Comparative Example 1

[0122] The preparation method of the pharmaceutical composition of this comparative example is the same as that of Example 1, the only difference being that no excipient is added to the sample of this comparative example. The sample is atomized according to the method of Example 1, and the measurement results are shown in Table 6.

[0123] Table 6 Particle size, PDI and encapsulation efficiency of LNP before and after atomization in Comparative Example 1

[0124]

[0125] It can be seen from the above table that no excipients were added to the samples prepared in the above comparative examples, and the particle size and PDI were significantly increased after atomization. In the above Examples 1, 8-12, the LNP particle size was reduced after adding excipients 0.1% (w / v) Tween 80, 0.5% (w / v) Poloxamer 188 or 0.1% (w / v) Triton, and the PDI was less than 0.3. At the same time, the combination of excipients 0.05% (w / v) T80 & 0.05% (w / v) P188 had an atomization stabilization effect that was almost the same as that of 0.1% (w / v) T80. Overall, Tween 80 had a better stabilization effect.

[0126] Stability test:

[0127] The CT102-LNP solution prepared in Comparative Example 1 without Tween 80 was placed at 2-8°C for 6 months. The particle size increased significantly in January, and there was no significant change in the particle size during January to June. The results are shown in Table 8. Similarly, the CT102-LNP sample prepared in Example 1 was treated in the same manner to determine its stability. The results are shown in Tables 7 and 8. Figure 3 As shown, its particle size and encapsulation efficiency did not change significantly, and the stability was good. Specifically, under 2-8°C conditions, from 0 days to 6 months, the particle size increased within 3nm, PDI did not change significantly, and the encapsulation efficiency decreased within 3%, with no significant change. Example 1 Stability of the sample, adding 0.1% (w / v) T80 to the dispersion system is beneficial to prevent LNP aggregation and stabilize the particle size.

[0128] Table 7 Stability results of samples added with T80 in Example 1 at 2-8°C

[0129]

[0130] Table 8 Stability results of samples without T80 added in Comparative Example 1 at 2-8°C

[0131]

[0132] Comparative Examples 2-5

[0133] The preparation methods of Comparative Examples 2-5 are the same as those of Example 1, except that ionizable cationic lipids (YK-009, MC3, SM-102, ALC-0315) are used to replace the non-ionizable cationic lipid DOTAP. The samples are atomized according to the method of Example 1, and the experimental results are shown in Table 9.

[0134] Table 9 Sample composition, particle size before and after atomization, PDI and encapsulation efficiency results of this comparative example

[0135]

[0136] It can be seen from the above table that compared with Example 1, in the presence of Tween 80, the encapsulation efficiency of the ionizable cationic lipid LNP after atomization is significantly reduced, while the encapsulation efficiency of the DOTAP cationic lipid LNP after atomization in Example 1 remains basically unchanged, and the permanent cationic lipid has better stability.

[0137] Comparative Examples 6-8

[0138] The preparation method of this comparative example is the same as that of Example 1, except that different cationic lipids DOTMA or neutral lipids DPPC and DSPC are used in this comparative example to prepare LNP samples, and the samples are atomized by the method of Example 1. The experimental results are shown in Table 10.

[0139] Table 10 LNP sample composition, particle size before and after atomization, PDI and encapsulation efficiency results of this comparative example

[0140]

[0141] It can be seen from the above table that compared with Example 1, in Example 6, the neutral lipid is replaced with DPPC, and the encapsulation efficiency of LNP after atomization is reduced by 20%; when the cationic lipid is replaced with DOTMA and the neutral lipid is DSPC in Example 7, the particle size and PDI after atomization are significantly increased, and the encapsulation efficiency is reduced by less than 10%; in Example 8, the neutral lipid is replaced with DPPC, and the encapsulation efficiency of LNP after atomization is reduced by 30%; Compared with Example 1, DOTAP is a cationic lipid and DSPC is a neutral lipid. The particle size of the LNP after atomization is less than 200nm, and the encapsulation efficiency remains basically unchanged. The prescription of Example 1 has better atomization stability.

[0142] Embodiment 13

[0143] In vitro cell transfection experiments

[0144] Test samples: atomized solutions of the model samples of Example 1 at different concentrations.

[0145] Cell culture: Take the subcultured 95D, NCI-H4460, GLC-82 and A549 cell lines and dilute the logarithmically growing cells to 2-2.5×10 with 10% fetal bovine serum DMEM culture medium (supplemented with 100 kU / L of penicillin and streptomycin). 4 / ml concentration of cell suspension, add 3000-4000 cells per well into a 96-well cell culture plate, 100 μL per well, and culture until the cells adhere to the wall.

[0146] Transfection: When the cell abundance reaches 40-60% in a 96-well plate, the culture medium in each well is discarded, and CT102-LNP is transfected in a serum-free and antibiotic-free culture medium. Different concentrations of atomized test samples are added to each well according to the designed amount, and a positive control (cisplatin) and a cell control group are set up at the same time. The volume of each group of solutions is 100 μL, and 3 parallel wells are set up. After 6 hours of transfection, the culture medium in each well is discarded, and 100 μL of normal culture medium containing serum is added to each well, and the cells are placed in a 37°C, 5% CO2 incubator for further cultivation for 72 hours.

[0147] Cell viability detection: The MTT method was used to detect the growth inhibition of lung cancer cells by the test samples. The results are shown in Table 11.

[0148] Table 11 Determination of the inhibitory effect of the model samples of Example 1 on the proliferation of various lung cancer cells

[0149]

[0150] As can be seen from Table 11, the atomized CT102-LNP has a strong proliferation inhibitory effect on the four lung cancer cells, and the inhibitory effect is equivalent to that of the positive control cisplatin at 0.2 mg / mL.

[0151] Embodiment 14

[0152] Animal in vivo testing

[0153] (1) Establishment of mouse lung cancer transplant model: When the NCI-H446 human small lung cancer cells in the culture flask grow to a density of 70-80%, tumor inoculation is started. The subcultured tumor cells are digested into a suspension under sterile conditions, rinsed with sodium chloride injection and resuspended into a suspension. 1 mL of the cell suspension is drawn with a syringe and subcutaneously injected with 200 μL of NCI-H446 lung cancer cell suspension per mouse on the right side of the chest near the mid-axillary line. After tumor inoculation, the mice are routinely raised in an SPF-grade mouse breeding room.

[0154] (2) Experimental grouping and treatment scheme: After successful modeling, the mice were randomly divided into 3 groups, namely, a blank model control group (given saline), a CT102-LNP treatment group prepared in Example 1, and a positive drug (cisplatin) treatment group, with 11 mice in each group. The mice were administered by aerosol inhalation, with continuous aerosolization for 15 minutes, and the drug was administered once every 24 hours for a total of 28 days. The positive control group was administered by tail vein injection, and the weight of mice in each group was measured and recorded on the 7th, 14th, 21st and 28th days of administration. After the experimental cycle of each group of mice was completed, the remaining mice were killed, the tumor tissue was peeled off, the tumor mass was weighed, and the tumor inhibition rate was calculated. The results are shown in Table 12.

[0155] Table 12 Body weight changes of mice after administration

[0156]

[0157] As can be seen from Table 12, the body weight of mice in the blank control group showed an upward trend, and the body weight on the 28th day increased by 3.0% compared with the 7th day; the body weight of mice in each drug-treated group decreased. On the 28th day, the average body weight of mice was reduced by 5.3% in the positive control group and 5.5% in the CT102-LNP treatment group compared with the blank control group (see Figure 4 ). This indicates that aerosolized antisense oligonucleotides can effectively inhibit the growth of lung cancer tumors, and the inhibitory effect is comparable to that of the positive control cisplatin.

[0158] Table 13. Tumor mass after administration in mice

[0159]

[0160] As shown in Table 13, the average tumor weight of the transplanted tumors in the blank control group was 0.150±0.016 g, the positive control cisplatin group was 0.052±0.014 g, and the CT102-LNP treatment group was 0.057±0.013 g (see Figure 5 ), compared with the blank model control group, the tumor inhibition rate of the positive control cisplatin group was 65.34%, and the tumor inhibition rate of the CT102-LNP treatment group was 62.00%. The tumor weights of the drug-treated groups were significantly reduced, and the CT102-LNP treatment group was equivalent to the positive control cisplatin. Atomized inhalation of CT102-LNP can inhibit the growth of human NCI-H446 small cell lung cancer tumors.

[0161] The preferred embodiments of the present disclosure are described in detail above; however, the present disclosure is not limited to the specific details in the above embodiments. Within the technical concept of the present disclosure, a variety of simple modifications can be made to the technical solution of the present disclosure, and these simple modifications all fall within the protection scope of the present disclosure.

[0162] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present disclosure will not further describe various possible combinations.

[0163] In addition, various embodiments of the present disclosure may be arbitrarily combined, and as long as they do not violate the concept of the present disclosure, they should also be regarded as the contents disclosed by the present disclosure.

Claims

1. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises lipids, nucleic acids encapsulated in the lipids, and a dispersion system solution added with a water-soluble excipient; The lipids include 40-60 mol % of non-ionizable cationic lipids, 10-20 mol % of neutral lipids, 1-5 mol % of long-circulating lipids and 30-50 mol % of cholesterol; Wherein, the non-ionizable cationic lipid is (2,3-dioleoyl-propyl)-trimethylammonium-chloride, the neutral lipid is distearoylphosphatidylcholine, and the long-circulating lipid is dimyristoylglycerol-3-methoxypolyethylene glycol 2000; The dosage ratio of the non-ionizable cationic lipid to the nucleic acid is expressed as an N / P ratio, and the N / P ratio is (3:1)-(10:1); The water-soluble excipient is Tween 80, and the concentration of the water-soluble excipient is 0.01-0.5% (w / v); The nucleic acid is an antisense oligonucleotide; the antisense oligonucleotide is CT102, and the nucleotide sequence of CT102 is: 5'-TCCTCCGGAGCCAGACTTCA-3'; The particle size of the pharmaceutical composition is 50-200 nm, and the polydispersity index of the pharmaceutical composition is no greater than 0.

3.

2. The pharmaceutical composition according to claim 1, wherein The dispersion system solution is at least one selected from Tris buffer, DPBS buffer, HEPES buffer, PBS buffer, citrate buffer, phosphate buffer, carbonate buffer and acetate buffer.

3. A method for preparing the pharmaceutical composition according to any one of claims 1 to 2, characterized in that: The method comprises the following steps: S1, dissolving the lipid in an organic solvent to obtain a first dispersion; S2, dissolving the nucleic acid in the first dispersion system solution to obtain a second dispersion solution; S3, mixing the first dispersion liquid and the second dispersion liquid using a microfluidic method to obtain a lipid nanoparticle intermediate solution; S4. Use the second dispersed system solution to ultrafilter the lipid nanoparticle intermediate solution to remove the organic solvent, add the water-soluble excipient, and mix until uniform.

4. The method according to claim 3, wherein: The organic solvent is any one selected from ethanol, acetone and N, N-dimethylformamide; The first dispersed system solution is at least one selected from a citrate buffer and an acetate buffer; The second dispersed system solution is at least one selected from Tris buffer, DPBS buffer and HEPES buffer.

5. Use of the pharmaceutical composition according to any one of claims 1 to 2 and / or the pharmaceutical composition prepared by the method according to any one of claims 3 to 4 in the preparation of anti-tumor drugs, characterized in that: The anti-tumor drug is administered by aerosol inhalation; The device for atomization inhalation is any one selected from a compression nebulizer, a vibrating mesh nebulizer and a soft mist inhaler.